- Home
- PCRX vs ATRO Comparison
PCRX vs ATRO Comparison
Compare PCRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ATRO
- Stock Information
- Founded
- PCRX 2006
- ATRO 1968
- Country
- PCRX United States
- ATRO United States
- Employees
- PCRX N/A
- ATRO N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- PCRX Health Care
- ATRO Industrials
- Exchange
- PCRX Nasdaq
- ATRO Nasdaq
- Market Cap
- PCRX 1.2B
- ATRO 1.2B
- IPO Year
- PCRX 2011
- ATRO N/A
- Fundamental
- Price
- PCRX $27.12
- ATRO $39.89
- Analyst Decision
- PCRX Buy
- ATRO Strong Buy
- Analyst Count
- PCRX 6
- ATRO 1
- Target Price
- PCRX $30.00
- ATRO $49.00
- AVG Volume (30 Days)
- PCRX 634.1K
- ATRO 1.1M
- Earning Date
- PCRX 11-05-2025
- ATRO 11-05-2025
- Dividend Yield
- PCRX N/A
- ATRO N/A
- EPS Growth
- PCRX N/A
- ATRO N/A
- EPS
- PCRX N/A
- ATRO N/A
- Revenue
- PCRX $705,848,000.00
- ATRO $822,852,000.00
- Revenue This Year
- PCRX $7.36
- ATRO $9.05
- Revenue Next Year
- PCRX $10.07
- ATRO $6.88
- P/E Ratio
- PCRX N/A
- ATRO N/A
- Revenue Growth
- PCRX 2.25
- ATRO 10.99
- 52 Week Low
- PCRX $12.61
- ATRO $14.13
- 52 Week High
- PCRX $27.64
- ATRO $46.61
- Technical
- Relative Strength Index (RSI)
- PCRX 64.42
- ATRO 58.68
- Support Level
- PCRX $25.63
- ATRO $39.24
- Resistance Level
- PCRX $27.11
- ATRO $46.61
- Average True Range (ATR)
- PCRX 0.90
- ATRO 2.09
- MACD
- PCRX -0.03
- ATRO 0.37
- Stochastic Oscillator
- PCRX 79.20
- ATRO 39.08
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.